Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
3D Ultrasound Breast Imaging
NCT04692818
Recruiting
The purpose of this research is to study the efficacy of a new ultrasound imaging method for diagnosis of breast mass.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Breast Tumor
Register for Updates
Geniculate Artery Embolization for Osteoarthritis
NCT04456569
Recruiting
The need for exploration of more definitive and cost effective non-arthroplasty treatments of osteoarthritis (OA) has been demonstrated by the orthopedic and health economic research. Embolotherapy of neovessels associated with OA joints has been shown to be promising in patients with knee OA. There is a need for level one evidence drawn from randomized clinical trials to prove the safety, feasibility and efficacy of knee embolotherapy compared to standard of care. This randomized pilot study... Read More
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
06/27/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Osteo Arthritis Knee, Arthritis, Osteoarthritis, Osteoarthritis, Knee
Register for Updates
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737
Recruiting
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy,
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0032), Saint Louis Park, Minnesota
Conditions: Prostate Cancer, Prostatic Neoplasms
Register for Updates
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
NCT06071845
Recruiting
This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy. Non-endoscopic swallowable encapsulate sponge cell collection devices combined with markers for BE/esophageal adenocarcinoma (EAC) detection are a guideline-endorsed alternative to endoscopy for BE screening. The Oncoguard registered trademark Esophagus test (OGE) test uses esophageal cytology specimens collected with a minim... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/26/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Barrett Esophagus, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia, Esophageal Adenocarcinoma
Register for Updates
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT05962346
Recruiting
The purpose of this research is to gather information on the safety and effectiveness of a procedure called Fetoscopic Endoluminal Tracheal Occlusion (FETO) at Mayo Clinic. The intent of the FETO procedure is to improve development of the lungs in fetuses diagnosed with severe congenital diaphragmatic hernia (CDH).
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
06/26/2025
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Congenital Diaphragmatic Hernia
Register for Updates
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510
Recruiting
The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once eve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: HealthPartners Institute, Cancer Research Center - 1143, Saint Louis Park, Minnesota
Conditions: Non Small Cell Lung Cancer
Register for Updates
Fenofibrate for Prevention of DR Worsening
NCT04661358
Recruiting
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborate with a primary care provider such as an internist/endocrinologist to prescribe and monitor the dru... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/26/2025
Locations: Retina Center, PA DBA Retina Center of Minnesota, Minneapolis, Minnesota
Conditions: Diabetic Retinopathy
Register for Updates
Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases
NCT06745024
Recruiting
This phase III trial compares the effect of adding radiation therapy to usual care on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causing symptoms (asymptomatic). High-risk bone metastases are defined by their location (including hip, shoulder, long bones, and certain levels of the spine), or size (2 cm or larger). These bone metastases appear to be at higher risk of complications such as fracture, spinal cord compression, and/or pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota
Conditions: Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
Register for Updates
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
NCT06689956
Recruiting
This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.
Gender:
ALL
Ages:
All
Trial Updated:
06/25/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023
Register for Updates
Somatic Mosaicism in Twins Discordant for Childhood Cancer
NCT06054295
Recruiting
Somatic mosaicism in cancer associated genes is one potential explanation for discordance in childhood cancer that has not been fully explored to date. This pilot study will focus on twins with central nervous system (CNS) tumors who are identified through the Children's Oncology Group's Project: EveryChild (PEC) registry or volunteer.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
06/25/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Pediatric Central Nervous System Tumor, Central Nervous System Tumor, Discordant Twin, Somatic Mutation
Register for Updates
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT05465941
Recruiting
This phase II trial tests whether pegylated SN-38 conjugate PLX038 (PLX038) works to shrink tumors in patients with ovarian, primary peritoneal, and fallopian tube cancers that has spread from where it first started (primary site) to other places in the body (metastatic). PLX038 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Register for Updates
Distal Radius Interventions for Fracture Treatment
NCT05131685
Recruiting
This protocol describes a multicenter, prospective randomized superiority trial comparing functional outcomes between children treated with sedated reduction versus no formal reduction.
Gender:
ALL
Ages:
Between 4 years and 10 years
Trial Updated:
06/25/2025
Locations: TRIA Health Partners, Minneapolis, Minnesota
Conditions: Fracture Distal Radius
Register for Updates